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Infertility affects approximately 10%–15% of reproductive‑aged couples. In Nigeria, it is an important reproductive health 
issue and a common reason for gynecological clinic consultations. Significant improvements in fertility treatment have 
made it possible for many patients to conceive with medical assistance. For example, women with fallopian tube blockage 
can conceive with in vitro fertilization (IVF). Modern IVF generally involves controlled ovarian stimulation with exogenous 
gonadotropins, oocytes collection through transvaginal ultrasonographic‑guided aspiration, coculture of eggs and sperm 
in culture (or intracytoplasmic injection of sperm into the oocyte), and placement of the resultant embryos (2–5 d later) 
directly into the uterus. Some of the major drawbacks to IVF are its high cost of treatment and paucity of availability in our 
sub‑Saharan region.
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Introduction
I n fe r t i l i t y  wh i ch  i s  de f ined  a s  the  f a i l u re  to 
conceive (irrespective of cause) after 1 year of unprotected 
intercourse is a major challenge worldwide and it affects 
about 10%–15% of reproductive-aged couples. Although its 
overall prevalence has been stable for some years, a shift 
in the etiology mainly due to patient’s age has occurred. 
As a woman’s age increases, the risk of infertility also 
increases.
Despite the definition of infertility, the chances of achieving 
pregnancy per menstrual cycle (fecundability) are lower 
in older women. Withholding treatment for 1 year in 
a 40-year-old woman seeking fertility services may be 
inappropriate. In women older than 35 years, a complete 
evaluation after 4–6 months of trying to conceive is prudent 
because their response to treatment may be reduced due to 
diminished ovarian reserve.
To achieve pregnancy, the integrity of the female and male 
reproductive tracts must be intact and these involve the release 
of a normal oocyte, the production of adequate spermatozoa, 
the normal transport of the gametes to the fallopian tube 
where fertilization occurs, and finally, the subsequent transport 
of the cleaving embryo into a normal endometrial cavity for 
implantation and development. Male and female factors 
contribute about 35% each to infertility. Combined male 
and female factors contribute to 20% of infertility, and in the 
remaining 10% of cases, the cause is unknown. Other factors 
associated with an increased risk of infertility are lifestyle, 
environmental, and occupational factors. These include toxic 
effects of tobacco/marijuana or other drugs use, excessive 
exercise, inadequate diet associated with extreme weight loss 
or gain, and very importantly, advanced maternal age.
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Significant improvements in fertility treatment have made 
it possible for many patients to conceive with medical 
assistance. For example, women with fallopian tube 
blockage can conceive with in vitro fertilization (IVF). Men 
with severe oligospermia or obstructive azoospermia but 
have sperm on a testicular biopsy or epididymal sperm 
aspiration can have a family using IVF/intracytoplasmic 
sperm injection (ICSI).
Since the first successful human IVF treatment in 1978 with the 
delivery of Louise Brown in England,[1] there has been greater 
understanding of the ovulatory process. This pioneering 
work of Edwards and Steptoe has been replicated worldwide, 
and IVF is now recognized as an established treatment for 
infertility. Subsequently, helpless infertile couples are now 
able to achieve pregnancy and patients who were considered 
sterile in the past are now capable of having children.
The indications for IVF treatment have shifted from the 
narrow scope of tubal infertility to other indications that 
were almost impossible to overcome before now, including 
oligospermia and obstructive azoospermia. Patients with a 
history of endometriosis unsuccessfully treated medically 
or surgically and patients with failed conservative fertility 
treatment or those with unexplained infertility may benefit 
from IVF. Finally, adults and children with cancer can have 
fertility preservation done early in their treatment process 
thus making it possible for them to achieve their dreams of 
having their own babies.
In Vitro Fertilization Procedure
The procedure for IVF treatment comprises retrieving 
preovulatory oocytes from the ovary, subsequent fertilization 
with sperm in the laboratory and embryo transfer into the 









Ovarian Stimulation for In Vitro Fertilization
The success of an IVF treatment is dependent on the 
patient’s age and the quality of embryos transferred into 
the endometrial cavity, among other factors.[2-4] The number 
Figure 2:  Two pronuclei stage embryo – 18 h postinsemination
Figure 1: Metaphase II preovulatory oocyte
Figure 4: 10–12 cells embryoFigure 3: Eight cells stage embryo
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of embryos obtained in any given IVF cycle depends on the 
number of oocytes retrieved after ovulation induction.
Ovarian stimulation is done mainly using gonadotropins (human 
menopausal gonadotropin such as Menogon Humog, pure 
follicle-stimulating hormone (FSH), and recombinant 
FSH/luteinizing hormone (LH) such as Menopur and Gonal-F). 
The doses of gonadotropins vary from 150 to 450 IU/day, 
depending on the patient’s age, ovarian reserve, and previous 
history. The use of gonadotropins in ovarian stimulation has 
led to an overall improvement in IVF. This is due to increase 
in the number, quality, and synchronization of the retrieved 
oocytes per cycle leading to the improvement in fertilization 
rates, increase in the number of embryos, and the subsequent 
pregnancy rate.[5]
Furthermore, because more embryos are available, an 
opportunity exists for cryopreservation of the excessive 
number of embryos for the future transfer(s). In general, 
patients start treatment on the 2nd or 3rd day of the menstrual 
cycle. The response is basically monitored using transvaginal 
ultrasonography. Once at least four follicles reach 17–18 mm 
in diameter, the gonadotropins are discontinued, and 
10,000 IU of human chorionic gonadotropins (HCGs) is 
administered. Oocyte retrieval is performed about 34–36 h 
later.
The two most common protocols available for ovarian 
stimulation are the gonadotropin-releasing hormone (GnRH) 
agonist and the GnRH antagonist protocols and both are 
based on the principles of follicular recruitment, selection, 
and dominance. Examples of the commonly used GnRH 
agonist in our environment are buserelin, luprodex, and 
zoladex, and for the antagonist, we have cetrotide.
In the GnRH agonist’s protocol, the pituitary gland undergoes 
an initial downregulation leading to the prevention of 
spontaneous LH surge and premature luteinization. The GnRH 
agonists can be used in two protocols known as the flare-up 
protocol and the luteal-phase protocol.[5-8] The flare-up 
protocol has the advantage of using the transitory elevation 
of FSH (agonist effect) that occurs during the first 4 days 
of the follicular phase. This elevation helps in the follicular 
recruitment process, and the administration of gonadotropins 
must be initiated on the third menstrual cycle day.[5]
In the luteal-phase protocol, GnRHa is started in the mid-luteal 
phase, and by the onset of the subsequent menstrual 
cycle, the phenomenon of pituitary downregulation has 
been achieved. The administration of the gonadotropins 
commences on the 2nd day of bleeding.[7,8]
Potential risks and disadvantages with the use of GnRHa 
protocol include increased requirements of gonadotropins, 
increased costs due to additional days of therapy, and the 
risk of ovarian hyperstimulation syndrome.
Figure 5: Blastocysts Figure 6: Catheters for embryo transfer
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With the GnRH antagonist protocol, the GnRH antagonists are 
administered when the largest follicle reaches a diameter of 
14 mm or when the LH levels in serum are >10 mIU/mL.[9] This 
is usually from day 6 or 7 of gonadotropins administration. 
GnRH antagonists have the advantage of blocking the LH 
surge at the periovulatory period; therefore, premature 
luteinization or spontaneous LH surge does not occur. 
Because the pituitary gland is not downregulated at the 
beginning of the menstrual cycle, smaller amounts of 
gonadotropins are required for ovarian stimulation. Another 
advantage with this protocol is that preovulatory LH surge 
can be achieved using GnRH agonist and therefore avoiding 
the long-term effects of the HCG injection that is responsible 
for triggering ovarian hyperstimulation syndrome.
Follicular Aspiration
Follicular aspiration is performed 34–36 h after the ovulation 
trigger. This is usually done under transvaginal ultrasound 
guidance. The patient is placed in the dorsal lithotomy 
position and sedation administered. The vaginal wall is 
cleaned with saline, and a transvaginal ultrasound probe 
with a sterile cover, attached to a needle guide is inserted in 
the vagina to localize the ovaries and the follicles. An oocyte 
retrieval needle is subsequently passed through the needle 
guide through the vaginal fornix into the ovaries, and the 
follicular fluid is aspirated. The fluid is then transferred to 
the IVF laboratory to confirm the presence of oocytes. The 
major risks of this procedure are infection and damage to the 
pelvic vessels and organs. These risks are, however, almost 
nonexistent when carefully performed and in trained hands.[10]
Oocyte Classification
The quality of the oocytes collected is an important 
determinant of IVF treatment success.[11] The follicular 
fluid is examined under a microscope for the oocytes 
which are graded according to the appearance of 
the corona-cumulus complex. The presence of a 
polar body (metaphase II  stage) and/or germinal 
vesicle (prophase stage) is a determining factor for the 
preincubation time before the insemination.
Sperm Preparation and Oocyte Insemination
Semen sample is collected immediately before oocyte 
collection, usually after 3–5 days of sexual abstinence. The 
sample is then processed to retain only the motile and 
morphologically normal fraction of the sperm. This is done 
with centrifugation through a density gradient system or 
simple media wash for poor quality samples that may have 
poor recoveries with the gradient system. The sperm is 
incubated for 60 min in an atmosphere of 5% carbon dioxide 
in the air. Finally, the supernatant containing the motile 
fraction of sperm is removed, and oocyte insemination or 
ICSI performed.
Embryo Culture
The inseminated oocytes are incubated in an atmosphere 
of 5% carbon dioxide in the air with 98% humidity. Ideally, 
fertilization occurs approximately 18 h after insemination, 
and this is evidenced by the presence of two pronuclei and the 
extrusion of a second polar body. Fertilized oocytes (embryos) 
are transferred into growth media in the incubator and are 
subsequently monitored for divisions. A 4–8 cell stage 
embryo is seen about 36–48 h after insemination and then 
10–16 cells after 48–72 h. The morula or blastocyst stage is 
observed after 96–120 h. Embryos are classified according 
to symmetry, presence of fragments, clarity, and number of 
blastomeres [Figures 1-5].[11]
Embryo Transfer
Transcervical transfer under transabdominal ultrasonography 
is the most common method used for embryo transfer. 
The procedure is usually performed on day 3 after oocyte 
insemination or when the embryo reaches the blastocyst 
stage on day 5.[12-15]
Several catheters have been designed for embryo transfer, 
and the choice of catheter is a matter of physician 
preference as it does not affect pregnancy rate [Figure 6]. 
The embryos are loaded with 15–20 µL of culture media, 
the catheter is advanced into the uterine cavity, and the 
embryos ejected into the mid-cavity, approximately 1–2 cm 
from the fundus. Elective single blastocyst transfer reduces 
multiple pregnancy rates.[16]
Management of the Luteal Phase
Recent publications support the benefits of supporting 
the luteal phase with exogenous progesterone which 
is usually commenced after oocyte retrieval.[2] The 
administration of exogenous progesterone stems from 
the possible induction of an abnormal endocrine balance 
from superovulation and aspiration of granulosa cells 
at the time of oocyte retrieval.[17] Several preparations 
are available including natural progesterone in oil base 
administered intramuscularly (e.g., gestone), vaginal 
progesterone suppositories (e.g., cyclogest), and capsules 
of micronized progesterone.[18] The administration of 
progesterone is continued until the day of the pregnancy 
test, and if the pregnancy test result is positive, the 
hormonal support may be continued until the 10th week 
of pregnancy.
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Outcomes of Assisted Reproductive Technologies
It is estimated that more than 5 million children have 
been conceived worldwide since the first IVF pregnancy 
in 1978.[19,20] The ultimate goal of an IVF treatment is 
achieving a live birth; however, clinical pregnancy rate is 
the best indicator for evaluating IVF treatment. Globally, 
the average clinical pregnancy rate per embryo transfer 
ranges from 30% to 45%[21-23] although pregnancy and live 
birth rates vary significantly with the female partner’s age. 
In one study, the overall pregnancy and live birth rates for 
all the IVF treatments in the United States of American 
were 35% and 28.6%, respectively.[23] The pregnancy rate by 
patient age was approximately 44.7%, 37.7%, 27.6%, 17.7%, 
and 9.2% for women younger than 35 years, 35–37 years, 
38–40 years, 41–42 years, and 43–44 years, respectively. In 
that same study, the percentage of twins and other higher 
multiples were 28.8% and 2.1%, respectively. The incidence 
of miscarriages, stillbirths, congenital malformations, and 
chromosome abnormalities in IVF pregnancy is similar to 
that of general population.
Ectopic pregnancy has been reported after IVF probably due 
to the migration of the embryo through the corneal ostium. 
Ectopic pregnancy occurs in approximately 0.7% of cases. 
In some instances, ectopic pregnancy is associated with 
heterotopic pregnancy.
Conclusion
Since the delivery of the first IVF baby in 1978, millions of 
babies have been delivered worldwide through this process, 
and many infertile couples have been able to fulfill their 
dreams of having a family. However, the optimal strategy for 
treating infertile couples is not always clear, and IVF is not 
always the first treatment of choice for many infertile couples. 
Appropriate treatments for a couple with unexplained 
infertility may also include intrauterine insemination and 
ovulation induction, either alone or in combination as these 
treatments are less expensive and more cost-effective than 
IVF; however, the pregnancy rates associated with these 
methods (typically between 5% and 15% per cycle) are well 
below those achieved with IVF.
Some of the major drawbacks to IVF are its high cost and 
the paucity of available centers offering the treatment in the 
sub-Saharan region. There is poor government support, and 
in the majority of cases, the treatment is not supported by 
health management organizations or insurance companies, 
leaving the patients with a huge out of pocket expenditure 
for their treatment. It is, therefore, pertinent to ensure proper 
patient selection before commencement of IVF, as many 
patients will benefit from other cheaper forms of fertility 
treatment.
Its worthy to note that studies have not shown any significant 
difference in pregnancy outcomes between spontaneously 
conceived and IVF pregnancies.
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